<DOC>
	<DOC>NCT01576575</DOC>
	<brief_summary>The purpose of this study is to determine how people absorb and break down (metabolize) and eliminate buprenorphine and if CYP3A is involved.</brief_summary>
	<brief_title>Buprenorphine Disposition and Clinical Effects</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Each subject must meet all of the following criteria: 1. Male or nonpregnant female volunteer, 1850 yr old 2. Good general health with no known major medical conditions 3. BMI between 2033 4. Provide informed consent Subjects will not be enrolled if any of the following criteria exist: 1. Known history of liver or kidney disease 2. Use of prescription or nonprescription medications, herbals or foods known to be metabolized by or affect CYP3A activity (this includes the use of oral contraceptives). 3. Females who are pregnant or nursing 4. Known history of drug or alcohol addiction (prior or present addiction or addiction treatment) 5. Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>to determine how people absorb and break down (metabolize) and eliminate buprenorphine and if CYP3A is involved.</keyword>
</DOC>